Nonpeptide Urotensin-II receptor agonists and antagonists: Review and structure-activity relationships

Peptides

Volumn 29, Issue 5, 2008, Pages 680-690

  Lescot, Elodie ^a   Bureau, Ronan ^a   Rault, Sylvain ^a  

^a CENTRE D ETUDES ET DE RECHERCHE SUR LE MÉDICAMENT DE NORMANDIE   (France)

Author keywords

GPCR; GPR14; Nonpeptide agonists and antagonists; Pharmacophore; SAR; Urotensin II

Indexed keywords

AC 7954; AMIDE; BENZAZEPINE DERIVATIVE; BIM 23127; FL 104; FL 68; G PROTEIN COUPLED RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; HORMONE RECEPTOR STIMULATING AGENT; OCTREOTIDE; PALOSURAN; PYRROLIDINE DERIVATIVE; QUINOLINE DERIVATIVE; S 6716; SB 328872; SB 436811; SB 611812; SB 706375; SB 710411; SULFONAMIDE; UNCLASSIFIED DRUG; UREA DERIVATIVE; UROTENSIN II AGONIST; UROTENSIN II ANTAGONIST;

ARTICLE; ENANTIOMER; GASTROINTESTINAL DISEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HUMAN; MOLECULAR MODEL; NEUROENDOCRINE TUMOR; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

BENZAZEPINES; HUMANS; HYDROGEN BONDING; LIGANDS; MOLECULAR STRUCTURE; PROTEIN CONFORMATION; PYRROLIDINES; QUINOLINES; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; UREA; UROTENSINS;

EID: 42049110102     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2007.09.019     Document Type: Article

References (81)

1. Aissaoui H, Binkert C, Clozel M, Mathys B, Mueller C, Nayler O, et al. Actelion Pharmaceuticals Ltd. (assignee). Preparation of 1-(piperazinylalkyl)-3-quinolinylurea derivatives as urotensin II antagonists. PCT Int Appl.; 2004 (WO2004099179).
2. Aissaoui H, Binkert C, Clozel M, Mathys B, Mueller C, Nayler O, et al. Actelion Pharmaceuticals Ltd. (assignee). Preparation of novel piperidine derivatives as urotensin II antagonists. PCT Int Appl.; 2004 (WO2004099180).
3. Aissaoui H, Binkert C, Clozel M, Mathys B, Mueller C, Nayler O, et al. Actelion Pharmaceuticals Ltd. (assignee). Preparation of 1,2,3,4-tetrahydroisoquinolinyl ureas and related derivatives as urotensin II receptor antagonists. PCT Int Appl.; 2002 (WO2002076979).
4. Ames R.S., Sarau H.M., Chambers J.K., Willette R.N., Aiyar N.V., Romanic A.M., et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401 (1999) 282-286
5. Barton LS, Dodson JW, Gaitanopoulos DE, Girard GR, King BW, McAtee JJ, et al. Smithkline Beecham Corporation (assignee). Preparation of sulfonamides as antagonists of urotensin II. PCT Int Appl.; 2004 (WO2004043917).
6. Becker O.M., Marantz Y., Shacham S., Inbal B., Heifetz A., Kalid O., et al. G protein-coupled receptors: in silico drug discovery in 3D. Proc Natl Acad Sci USA 101 (2004) 11304-11309
7. Behm David J., Herold Christopher L., Ohlstein Eliot H., Knight Steven D., Dhanak D., and Douglas Stephen A. Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist. Br J Pharmacol 137 (2002) 449-458
8. Behm D.J., Harrison S.M., Ao Z., Maniscalco K., Pickering S.J., Grau E.V., et al. Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice. Br J Pharmacol 139 (2003) 464-472
9. Blakeney J.S., Reid R.C., Le G.T., and Fairlie D.P. Nonpeptidic ligands for peptide-activated G protein-coupled receptors. Chem Rev 107 (2007) 2960-3041
10. Bousette N., Hu F., Ohlstein E.H., Dhanak D., Douglas S.A., and Giaid A. Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation. J Mol Cell Cardiol 41 (2006) 285-295
11. Bousette N., Pottinger J., Ramli W., Ohlstein E.H., Dhanak D., Douglas S.A., et al. Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease. Peptides 27 (2006) 2919-2926
12. Brauner-Osborne H., and Brann M.R. Pharmacology of muscarinic acetylcholine receptor subtypes (m1-m5): high throughput assays in mammalian cells. Eur J Pharmacol 295 (1996) 93-102
13. Burstein E.S., Brauner-Osborne H., Spalding T.A., Conklin B.R., and Brann M.R. Interactions of muscarinic receptors with the heterotrimeric G proteins Gq and G12: transduction of proliferative signals. J Neurochem 68 (1997) 525-533
14. Burstein E.S., Spalding T.A., and Brann M.R. Pharmacology of muscarinic receptor subtypes constitutively activated by G proteins. Mol Pharmacol 51 (1997) 312-319
15. Carotenuto A., Grieco P., Campiglia P., Novellino E., and Rovero P. Unraveling the active conformation of urotensin II. J Med Chem 47 (2004) 1652-1661
16. Castel H., Diallo M., Chatenet D., Leprince J., Desrues L., Schouft M.T., et al. Biochemical and functional characterization of high-affinity urotensin II receptors in rat cortical astrocytes. J Neurochem 99 (2006) 582-595
17. Chatenet D., Dubessy C., Leprince J., Boularan C., Carlier L., Segalas-Milazzo I., et al. Structure-activity relationships and structural conformation of a novel urotensin II-related peptide. Peptides 25 (2004) 1819-1830
18. Clozel M., Binkert C., Birker-Robaczewska M., Boukhadra C., Ding S.S., Fischli W., et al. Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin system. J Pharmacol Exp Ther 311 (2004) 204-211
19. Clozel M., Hess P., Qiu C., Ding S.S., and Rey M. The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. J Pharmacol Exp Ther 316 (2006) 1115-1121
20. Conlon J.M., O'Harte F., Smith D.D., Tonon M.C., and Vaudry H. Isolation and primary structure of urotensin II from the brain of a tetrapod, the frog Rana ridibunda. Biochem Biophys Res Commun 188 (1992) 578-583
21. Coulouarn Y., Jegou S., Tostivint H., Vaudry H., and Lihrmann I. Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursors. FEBS Lett 457 (1999) 28-32
22. Coulouarn Y., Lihrmann I., Jegou S., Anouar Y., Tostivint H., Beauvillain J.C., et al. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA 95 (1998) 15803-15808
23. Croston G.E., Olsson R., Currier E.A., Burstein E.S., Weiner D., Nash N., et al. Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2-(dimethylamino)ethyl) isochroman-1-one (AC-7954). J Med Chem 45 (2002) 4950-4953
24. Dhanak D, Gallagher TF, Knight SD. Smithkline Beecham Corporation (assignee). Preparation of sulfonamides as antagonists of urotensin II. PCT Int Appl.; 2002 (WO2002090353).
25. Dhanak D, Gallagher TF, Knight SD. Smithkline Beecham Corporation (assignee). Preparation of sulfonamides as antagonists of urotensin II. PCT Int Appl.; 2002 (WO2002089740).
26. Dhanak D, Gallagher TF, Knight SD. Smithkline Beecham Corporation (assignee). Preparation of sulfonamides as antagonists of urotensin II. PCT Int Appl.; 2002 (WO2002089792).
27. Dhanak D, Gallagher TF, Knight SD. Smithkline Beecham Corporation (assignee). Preparation of sulfonamides as antagonists of urotensin II. PCT Int Appl.; 2002 (WO2002089793).
28. Dhanak D, Gallagher TF, Knight SD. Smithkline Beecham Corporation (assignee). Preparation of sulfonamides as antagonists of urotensin II. PCT Int Appl.; 2002 (WO2002090348).
29. Dhanak D, Gallagher TF, Knight SD, Schmidt SJ. Smithkline Beecham Corporation (assignee). Preparation of sulfonamides as antagonists of urotensin II. PCT Int Appl.; 2002 (WO2002089785).
30. Dhanak D, Gallagher TF, Knight SD, Schmidt SJ. Smithkline Beecham Corporation (assignee). Preparation of sulfonamides as antagonists of urotensin II. PCT Int Appl.; 2002 (WO2002090337).
31. Dhanak D, Knight SD. Smithkline Beecham Corporation (assignee). Sulfonamide derivative urotensin-II receptor antagonists, preparation, pharmaceutical compositions, and therapeutic use. PCT Int Appl.; 2001 (WO2001045694).
32. Dhanak D, Knight SD. Smithkline Beecham Corporation (assignee). Preparation of quinolones as urotensin-II receptor antagonists. PCT Int Appl.; 2002 (WO2002047456).
33. Dhanak D, Knight SD, Jin J, Keenan RM, Smithkline Beecham Corporation (assignee). Preparation of N-pyrrolidinyl and N-piperidinyl amide derivatives as urotensin-II receptor antagonists. PCT Int Appl.; 2001 (WO2001045711).
34. Dhanak D, Knight SD, Warren GL, Jin J, Widdowson KL, Keenan RM. Smithkline Beecham Corporation (assignee). Pyrrolidine derivative urotensin II receptor antagonists, their preparation, and therapeutic use. PCT Int Appl.; 2001 (WO2001045700).
35. Dodson JW, Ghavimi-Alagha B, Girard GR, King BW, McAtee JJ, Neeb MJ, et al. Smithkline Beecham Corporation (assignee). Preparation of sulfonamides as antagonists of urotensin II. PCT Int Appl.; 2004 (WO2004043366).
36. Douglas S.A., Behm D.J., Aiyar N.V., Naselsky D., Disa J., Brooks D.P., et al. Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375. Br J Pharmacol 145 (2005) 620-635
37. Douglas S.A., and Ohlstein E.H. Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med 10 (2000) 229-237
38. Douglas S.A., Sulpizio A.C., Piercy V., Sarau H.M., Ames R.S., Aiyar N.V., et al. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 131 (2000) 1262-1274
39. Dschietzig T., Bartsch C., Pregla R., Zurbrugg H.R., Armbruster F.P., Richter C., et al. Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure. Regul Pept 110 (2002) 33-38
40. Elshourbagy N, Shabon U. Protein and cDNA sequences of monkey urotensin II. PCT Int Appl.; 2002 (WO2002058323).
41. Elshourbagy N.A., Douglas S.A., Shabon U., Harrison S., Duddy G., Sechler J.L., et al. Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. Br J Pharmacol 136 (2002) 9-22
42. Evers A., and Klabunde T. Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. J Med Chem 48 (2005) 1088-1097
43. Evers A., and Klebe G. Ligand-supported homology modeling of G-protein-coupled receptor sites: models sufficient for successful virtual screening. Angew Chem Int Ed Engl 43 (2004) 248-251
44. Flohr S., Kurz M., Kostenis E., Brkovich A., Fournier A., and Klabunde T. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. J Med Chem 45 (2002) 1799-1805
45. Grieco P., Carotenuto A., Campiglia P., Zampelli E., Patacchini R., Maggi C.A., et al. A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge. J Med Chem 45 (2002) 4391-4394
46. Herold Christopher L., Behm David J., Buckley Peter T., Foley James J., Wixted William E., Sarau Henry M., et al. The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors. Br J Pharmacol 139 (2003) 203-207
47. Itoh H., Itoh Y., Rivier J., and Lederis K. Contraction of major artery segments of rat by fish neuropeptide urotensin II. Am J Physiol Regul Integr Physiol 252 (1987) R361-R366
48. Jin J., Dhanak D., Knight Steven D., Widdowson K., Aiyar N., Naselsky D., et al. Aminoalkoxybenzyl pyrrolidines as novel human urotensin-II receptor antagonists. Bioorg Med Chem Lett 15 (2005) 3229-3232
49. Kellenberger E., Springael J.Y., Parmentier M., Hachet-Haas M., Galzi J.L., and Rognan D. Identification of nonpeptide CCR5 receptor agonists by structure-based virtual screening. J Med Chem 50 (2007) 1294-1303
50. Kinney W.A., Almond Jr. H.R., Qi J., Smith C.E., Santulli R.J., de Garavilla L., et al. Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model. Angew Chem Int Ed Engl 41 (2002) 2940-2944
51. Kobilka B. Agonist binding: a multistep process. Mol Pharmacol 65 (2004) 1060-1062
52. Lamberts S.W., Krenning E.P., and Reubi J.C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endrocr. Rev. 12 (1991) 450-482
53. Lavecchia A., Cosconati S., and Novellino E. Architecture of the human urotensin II receptor: comparison of the binding domains of peptide and non-peptide urotensin II agonists. J Med Chem 48 (2005) 2480-2492
54. Lehmann F., Currier E.A., Olsson R., Hacksell U., and Luthman K. Isochromanone-based urotensin-II receptor agonists. Bioorg Med Chem 13 (2005) 3057-3068
55. Lehmann F., Lake L., Currier E.A., Olsson R., Hacksell U., and Luthman K. Design, parallel synthesis and SAR of novel urotensin II receptor agonists. Eur J Med Chem 42 (2007) 276-285
56. Lehmann F., Pettersen A., Currier E.A., Sherbukhin V., Olsson R., Hacksell U., et al. Novel potent and efficacious nonpeptidic urotensin II receptor agonists. J Med Chem 49 (2006) 2232-2240
57. Lescot E., Sopkova-de Oliveira Santos J., Dubessy C., Oulyadi H., Lesnard A., Vaudry H., et al. Definition of new pharmacophores for non-peptide antagonists of human Urotensin-II. Comparaison with the 3D-structure of human Urotensin-II and URP. J Chem Inf Mod 47 (2007) 602-612
58. Liu Q., Pong S.S., Zeng Z., Zhang Q., Howard A.D., Williams D.L.J., et al. Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem Biophys Res Commun 266 (1999) 174-178
59. Luthman K, Lehmann F. Acadia Pharmaceuticals Inc. (assignee). Amines and related compounds as UII-modulating compounds ant their preparation, pharmaceutical compositions, structure-activity relationship and use in the treatment of diseases. PCT Int Appl.; 2006 (WO2006135694).
60. Maguire J.J., Kuc E.K., and Davenport A.P. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol 131 (2000) 441-446
61. Marchese A., Heiber M., Nguyen T., Heng H.H., Saldivia V.R., Cheng R., et al. Cloning and chromosomal mapping of three novel genes, GPR9, GPR10, and GPR14, encoding receptors related to interleukin 8, neuropeptide Y, and somatostatin receptors. Genomics 29 (1995) 335-344
62. Mathys B, Mueller C, Scherz M, Weller T, Clozel M, Velker J, et al. Actelion Pharmaceuticals Ltd. (assignee). Preparation of pyridinyl ureas as urotensin II antagonists. PCT Int Appl.; 2005 (WO2005030209).
63. Matsushita M., Shichiri M., Imai T., Iwashina M., Tanaka H., Takasu N., et al. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens 19 (2001) 2185-2190
64. Melacini G., Zhu Q., and Goodman M. Multiconformational NMR analysis of sandostatin (octreotide): equilibrium between beta-sheet and partially helical structures. Biochemistry 36 (1997) 1233-1241
65. Mori M., Sugo T., Abe M., Shimomura Y., Kurihara M., Kitada C., et al. Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14). Biochem Biophys Res Commun 265 (1999) 123-129
66. Olsson R. Acadia Pharmaceuticals Inc. (assignee). A combinatorial scafford approach towards the pharmacophores of ligands II and somatostatin 5 receptors. PCT Int Appl.; 2004 (WO2004073642).
67. Ong K.L., Lam K.S., and Cheung B.M. Urotensin II: its function in health and its role in disease. Cardiovasc Drugs Ther 19 (2005) 65-75
68. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, A. FB, et al. Crystal structure of rhodopsin: a G-protein-coupled receptor. Science 2000;289:733-4.
69. Pearson D., Shively J.E., Clark B.R., Geschwind I., Barkley M., Nishioka R.S., et al. Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci USA 77 (1980) 5021-5024
70. Pohl E., Heine A., Sheldrick G.M., Dauter Z., Wilson K.S., Kallen J., et al. Structure of octreotide, a somatostatin analogue. Acta Crystallogr D: Biol Crystallogr 51 (1995) 48-59
71. Richards A.M., Nicholls M.G., Lainchbury J.G., Fisher S., and Yandle T.Y. Plasma urotensin II in heart failure. Lancet 360 (2002) 545-546
72. Rossowski W.J., Cheng B.L., Taylor J.E., Datta R., and Coy D.H. Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists. Eur J Pharmacol 438 (2002) 159-170
73. Sidharta P.N., Wagner F.D., Bohnemeier H., Jungnik A., Halabi A., Krähenbühl S., et al. Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clin Pharmacol Ther 80 (2006) 246-256
74. Spalding T.A., Burstein E.S., Brauner-Osborne H., Hill-Eubanks D., and Brann M.R. Pharmacology of a constitutively active muscarinic receptor generated by random mutagenesis. J Pharmacol Exp Ther 275 (1995) 1274-1279
75. Suguro T., Watanabe T., Ban Y., Kodate S., Misaki A., Hirano T., et al. Increased human Urotensin II levels are correlated with carotid atherosclerosis in essential hypertension. Am J Hypertens 20 (2007) 211-217
76. Tarui N, Santo T, Mori M, Watanabe H. Takeda Chemical Industries (assignee). Quinoline derivatives as vasoactive agents exhibiting orphan receptor GPR14 protein antagonism. PCT Int Appl.; 2001 (WO2001066143).
77. Tarui N, Santo T, Watanabe H, Aso K, Ishihara Y. Takeda Chemical Industries (assignee). Preparation of 2,3,4,5-tetrahydro-1H-3-benzazepine derivatives as GPR14 antagonists. PCT Int Appl.; 2002 (WO2002002530).
78. Tarui N, Santo T, Watanabe H, Aso K, Miwa T, Takekawa S. Takeda Chemical Industries (assignee). Preparation of biphenylcarboxamide compounds as GPR14 antagonists or somatostatin receptor regulators. PCT Int Appl.; 2002 (WO2002000606).
79. Totsune K., Takahashi K., Arihara Z., Sone M., Satoh F., Ito S., et al. Role of urotensin II in patients on dialysis. Lancet 358 (2001) 810-811
80. Tyndall J.D., Pfeiffer B., Abbenante G., and Fairlie D.P. Over one hundred peptide-activated G protein-coupled receptors recognize ligands with turn structure. Chem Rev 105 (2005) 793-826
81. Varady J., Wu X., Fang X., Min J., Hu Z., Levant B., et al. Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach. J Med Chem 46 (2003) 4377-4392